Ann: Positive Efficacy Data for ATH434 in a Primate Model of PD, page-14

Will be a huge upcoming months for this co. Could be a 10x, 40c by next year given upcoming results from human study on Parkinson disease

Parkinson's disease primate first data. This will top $100 today. AND ATH434 has been granted Orphan Drug designation for the treatment of MSA by the U.S. FDA and the European Commission. This designation entitles Alterity to seven years of market exclusivity in the U.S. and ten years of market exclusivity in the EU and qualifies Alterity for various development incentives, including U.S. tax credits for qualified clinical testing, reduced fees and access to EU-funded research grants.

IMHO, get in early. Look at IMU, IBX to name a few, which were trading below 1c, reached a high of 30/60c.

every biotech has its day.